+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Subcutaneous Immunoglobulin Market - Global Forecast 2026-2032- Product Image
Subcutaneous Immunoglobulin Market - Global Forecast 2026-2032- Product Image
Sale

Subcutaneous Immunoglobulin Market - Global Forecast 2026-2032

  • Report

  • 193 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 5889355
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Subcutaneous Immunoglobulin Market is projected to reach USD 12.94 Billion in 2026. It is expected to continue growing at a CAGR of 11.82%, reaching USD 25.45 Billion by 2032.

Subcutaneous Immunoglobulin: Executive Overview

Subcutaneous immunoglobulin (SCIG) is an established treatment approach for patients who require immunoglobulin replacement, particularly those with primary or selected secondary antibody deficiencies. It is administered into subcutaneous tissue, commonly through a pump or manual infusion system, and can support home-based care. Compared with intravenous administration, SCIG is associated with slower absorption and may offer greater scheduling flexibility, although suitability depends on clinical indication, product characteristics, patient preference, training, and access to support services.

How Home-Based Care Is Reshaping Immunoglobulin Delivery

The treatment landscape is shifting toward models that place greater emphasis on self-administration, home care, shared decision-making, and continuity of supply. These changes are supported by improved infusion devices, clearer patient education, remote follow-up, and clinical protocols designed to manage local reactions and adherence. Persistent constraints include product availability, reimbursement differences, training requirements, infusion-site burden, and the need for dependable plasma-derived supply chains.

Artificial Intelligence and the Next Phase of SCIG Care

Artificial intelligence can contribute to SCIG care through appointment coordination, adherence-risk identification, documentation support, patient education, and analysis of infusion records. Properly governed tools may help clinicians identify missed doses or emerging support needs earlier, but they do not replace immunology expertise or individualized assessment. Deployment should include validated data, privacy safeguards, explainability, bias monitoring, cybersecurity controls, and human review, especially when algorithms influence treatment decisions.

Regional Insights Across North America, Latin America, Europe, the Middle East, Africa, and Asia-Pacific

North America generally benefits from established immunology services, home-infusion infrastructure, and broader familiarity with self-administration, while coverage and out-of-pocket obligations remain important access determinants. Europe combines mature specialist care with differing national reimbursement, procurement, and home-treatment policies. Asia-Pacific includes advanced healthcare systems alongside settings where specialist access, cold-chain capacity, and patient training vary substantially. Latin America, the Middle East, and Africa face diverse challenges involving diagnosis, imported-product dependence, distribution reliability, and specialist availability; partnerships among public providers, hospitals, payers, and patient organizations can improve continuity and education.

Group-Level Priorities Across ASEAN, BRICS, the EU, G7, GCC, and NATO

ASEAN members must account for varied regulatory systems, healthcare capacity, and logistics across interconnected markets. BRICS countries present wide differences in domestic manufacturing capability, public procurement, specialist access, and affordability. European Union systems benefit from regulatory coordination but retain national differences in reimbursement and service delivery. G7 settings typically have stronger clinical infrastructure, yet must address aging populations, workforce pressure, and equitable access. GCC countries can leverage centralized procurement and specialized healthcare investment, while NATO members may place additional emphasis on resilient medical supply chains, emergency preparedness, and continuity of essential therapies.

Country Insights: Diverse Access, Delivery, and Policy Conditions

Australia and Canada must balance geographically dispersed populations with specialist and home-care support. Brazil, Mexico, India, China, Russia, and South Korea reflect different combinations of public coverage, domestic production, hospital capacity, and regional access. Japan, France, Germany, Italy, Spain, and the United Kingdom have established clinical systems but differ in reimbursement pathways, prescribing practices, and organization of home infusion. The United States has extensive specialty-care and home-infusion capabilities, while payer rules and patient cost exposure can affect treatment choice. Across all countries, reliable supply, diagnosis, education, and follow-up remain central to outcomes.

Actions for Leaders: Strengthen Access, Resilience, and Patient-Centered Delivery

Industry leaders should align product design and support services with patient capabilities, infusion frequency, tolerability, and home-care preferences. They should invest in nurse-led training, multilingual materials, accessible digital tools, and structured follow-up for new users. Supply resilience requires diversified sourcing, transparent allocation practices, quality controls, and contingency planning. Evidence generation should measure adherence, treatment burden, patient-reported outcomes, and healthcare utilization across diverse populations. AI initiatives should begin with narrowly defined workflows, clinical validation, governance, and measurable safety outcomes rather than unsupported automation.

Research Methodology: Evidence-Based Assessment of SCIG Dynamics

This executive summary uses a structured review of publicly available clinical guidance, regulatory information, peer-reviewed evidence, health-system practices, and policy considerations relevant to subcutaneous immunoglobulin. Findings are synthesized by delivery model, patient experience, infrastructure, access conditions, and technology readiness across the specified regions, groups, and countries. The assessment deliberately avoids market estimates, market sizing, forecasts, market shares, and company-specific analysis. Because reimbursement rules, product availability, and clinical guidance change over time, conclusions should be refreshed against current national sources before operational decisions are made.

Conclusion: Make SCIG More Reliable, Practical, and Equitable

SCIG is positioned within a broader transition toward flexible, patient-centered immunoglobulin care, with home administration and digital support serving as important enablers. Benefits will depend not only on the therapy itself but also on diagnosis, training, reimbursement, product continuity, clinical oversight, and local health-system capacity. Leaders that combine resilient supply, inclusive patient support, responsible technology adoption, and regionally tailored implementation can help make SCIG delivery safer, more convenient, and more equitable.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Subcutaneous Immunoglobulin Market, by Product Type
7.1. Introduction
7.2. Conventional Subcutaneous Immunoglobulin
7.2.1. Liquid Formulations
7.2.2. Lyophilized Formulations
7.3. Facilitated Subcutaneous Immunoglobulin
8. Subcutaneous Immunoglobulin Market, by Indication
8.1. Introduction
8.2. Primary Immunodeficiency
8.2.1. Common Variable Immunodeficiency
8.2.2. X Linked Agammaglobulinemia
8.3. Secondary Immunodeficiency
8.3.1. Chemotherapy Induced Immunodeficiency
8.3.2. Hematological Disorder Induced Immunodeficiency
9. Subcutaneous Immunoglobulin Market, by Strength
9.1. Introduction
9.2. Below 10 Percent
9.3. Between 10 To 20 Percent
9.4. Above 20 Percent
10. Subcutaneous Immunoglobulin Market, by Delivery Mode
10.1. Introduction
10.2. Manual Injection
10.3. Pump Administered
11. Subcutaneous Immunoglobulin Market, by End User
11.1. Introduction
11.2. Clinic
11.3. Home Healthcare
11.4. Hospital
12. Subcutaneous Immunoglobulin Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Subcutaneous Immunoglobulin Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Subcutaneous Immunoglobulin Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. ADMA Biologics, Inc.
16.2. argenx SE
16.3. Baxter International Inc.
16.4. Biological E. Limited
16.5. CSL Limited
16.6. Emergent BioSolutions Inc.
16.7. Grifols, S.A.
16.8. Intas Pharmaceuticals Limited
16.9. Japan Blood Products Organization
16.10. Kamada Ltd.
16.11. LFB S.A.
16.12. Octapharma AG
16.13. Pfizer Inc.
16.14. Sanquin Health Solutions B.V.
16.15. Shanghai RAAS Blood Products Co., Ltd.
16.16. Takeda Pharmaceutical Company Limited
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Subcutaneous Immunoglobulin Market, Years Considered for the Study
FIGURE 2. Global Subcutaneous Immunoglobulin Market, Research Design
FIGURE 3. Global Subcutaneous Immunoglobulin Market, Research Framework
FIGURE 4. Global Subcutaneous Immunoglobulin Market, Data Triangulation
FIGURE 5. Global Subcutaneous Immunoglobulin Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Subcutaneous Immunoglobulin Market Size, by Product Type, 2025 vs 2032 (%)
FIGURE 7. Global Subcutaneous Immunoglobulin Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Subcutaneous Immunoglobulin Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 9. Global Subcutaneous Immunoglobulin Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Subcutaneous Immunoglobulin Market Size, by Strength, 2025 vs 2032 (%)
FIGURE 11. Global Subcutaneous Immunoglobulin Market Size, by Strength, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Subcutaneous Immunoglobulin Market Size, by Delivery Mode, 2025 vs 2032 (%)
FIGURE 13. Global Subcutaneous Immunoglobulin Market Size, by Delivery Mode, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Subcutaneous Immunoglobulin Market Size, by End User, 2025 vs 2032 (%)
FIGURE 15. Global Subcutaneous Immunoglobulin Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Subcutaneous Immunoglobulin Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Subcutaneous Immunoglobulin Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Subcutaneous Immunoglobulin Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Subcutaneous Immunoglobulin Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Subcutaneous Immunoglobulin Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Subcutaneous Immunoglobulin Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Subcutaneous Immunoglobulin Market Segmentation & Coverage
TABLE 2. Global Subcutaneous Immunoglobulin Market Size, 2017-2032 (USD Million)
TABLE 3. Global Subcutaneous Immunoglobulin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 4. Global Conventional Subcutaneous Immunoglobulin Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Conventional Subcutaneous Immunoglobulin Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Conventional Subcutaneous Immunoglobulin Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Liquid Formulations Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Liquid Formulations Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Liquid Formulations Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Lyophilized Formulations Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Lyophilized Formulations Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Lyophilized Formulations Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Facilitated Subcutaneous Immunoglobulin Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Facilitated Subcutaneous Immunoglobulin Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Facilitated Subcutaneous Immunoglobulin Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Subcutaneous Immunoglobulin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 17. Global Primary Immunodeficiency Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Primary Immunodeficiency Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Primary Immunodeficiency Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Common Variable Immunodeficiency Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Common Variable Immunodeficiency Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Common Variable Immunodeficiency Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global X Linked Agammaglobulinemia Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global X Linked Agammaglobulinemia Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global X Linked Agammaglobulinemia Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global Secondary Immunodeficiency Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global Secondary Immunodeficiency Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global Secondary Immunodeficiency Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global Chemotherapy Induced Immunodeficiency Market Size, by Region, 2017-2032 (USD Million)
TABLE 30. Global Chemotherapy Induced Immunodeficiency Market Size, by Group, 2017-2032 (USD Million)
TABLE 31. Global Chemotherapy Induced Immunodeficiency Market Size, by Country, 2017-2032 (USD Million)
TABLE 32. Global Hematological Disorder Induced Immunodeficiency Market Size, by Region, 2017-2032 (USD Million)
TABLE 33. Global Hematological Disorder Induced Immunodeficiency Market Size, by Group, 2017-2032 (USD Million)
TABLE 34. Global Hematological Disorder Induced Immunodeficiency Market Size, by Country, 2017-2032 (USD Million)
TABLE 35. Global Subcutaneous Immunoglobulin Market Size, by Strength, 2017-2032 (USD Million)
TABLE 36. Global Below 10 Percent Market Size, by Region, 2017-2032 (USD Million)
TABLE 37. Global Below 10 Percent Market Size, by Group, 2017-2032 (USD Million)
TABLE 38. Global Below 10 Percent Market Size, by Country, 2017-2032 (USD Million)
TABLE 39. Global Between 10 To 20 Percent Market Size, by Region, 2017-2032 (USD Million)
TABLE 40. Global Between 10 To 20 Percent Market Size, by Group, 2017-2032 (USD Million)
TABLE 41. Global Between 10 To 20 Percent Market Size, by Country, 2017-2032 (USD Million)
TABLE 42. Global Above 20 Percent Market Size, by Region, 2017-2032 (USD Million)
TABLE 43. Global Above 20 Percent Market Size, by Group, 2017-2032 (USD Million)
TABLE 44. Global Above 20 Percent Market Size, by Country, 2017-2032 (USD Million)
TABLE 45. Global Subcutaneous Immunoglobulin Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 46. Global Manual Injection Market Size, by Region, 2017-2032 (USD Million)
TABLE 47. Global Manual Injection Market Size, by Group, 2017-2032 (USD Million)
TABLE 48. Global Manual Injection Market Size, by Country, 2017-2032 (USD Million)
TABLE 49. Global Pump Administered Market Size, by Region, 2017-2032 (USD Million)
TABLE 50. Global Pump Administered Market Size, by Group, 2017-2032 (USD Million)
TABLE 51. Global Pump Administered Market Size, by Country, 2017-2032 (USD Million)
TABLE 52. Global Subcutaneous Immunoglobulin Market Size, by End User, 2017-2032 (USD Million)
TABLE 53. Global Clinic Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Global Clinic Market Size, by Group, 2017-2032 (USD Million)
TABLE 55. Global Clinic Market Size, by Country, 2017-2032 (USD Million)
TABLE 56. Global Home Healthcare Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Global Home Healthcare Market Size, by Group, 2017-2032 (USD Million)
TABLE 58. Global Home Healthcare Market Size, by Country, 2017-2032 (USD Million)
TABLE 59. Global Hospital Market Size, by Region, 2017-2032 (USD Million)
TABLE 60. Global Hospital Market Size, by Group, 2017-2032 (USD Million)
TABLE 61. Global Hospital Market Size, by Country, 2017-2032 (USD Million)
TABLE 62. Global Subcutaneous Immunoglobulin Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. Asia-Pacific Subcutaneous Immunoglobulin Market Size, by Region, 2017-2032 (USD Million)
TABLE 64. Asia-Pacific Subcutaneous Immunoglobulin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 65. Asia-Pacific Subcutaneous Immunoglobulin Market Size, by Conventional Subcutaneous Immunoglobulin, 2017-2032 (USD Million)
TABLE 66. Asia-Pacific Subcutaneous Immunoglobulin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 67. Asia-Pacific Subcutaneous Immunoglobulin Market Size, by Primary Immunodeficiency, 2017-2032 (USD Million)
TABLE 68. Asia-Pacific Subcutaneous Immunoglobulin Market Size, by Secondary Immunodeficiency, 2017-2032 (USD Million)
TABLE 69. Asia-Pacific Subcutaneous Immunoglobulin Market Size, by Strength, 2017-2032 (USD Million)
TABLE 70. Asia-Pacific Subcutaneous Immunoglobulin Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 71. Asia-Pacific Subcutaneous Immunoglobulin Market Size, by End User, 2017-2032 (USD Million)
TABLE 72. North America Subcutaneous Immunoglobulin Market Size, by Region, 2017-2032 (USD Million)
TABLE 73. North America Subcutaneous Immunoglobulin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 74. North America Subcutaneous Immunoglobulin Market Size, by Conventional Subcutaneous Immunoglobulin, 2017-2032 (USD Million)
TABLE 75. North America Subcutaneous Immunoglobulin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 76. North America Subcutaneous Immunoglobulin Market Size, by Primary Immunodeficiency, 2017-2032 (USD Million)
TABLE 77. North America Subcutaneous Immunoglobulin Market Size, by Secondary Immunodeficiency, 2017-2032 (USD Million)
TABLE 78. North America Subcutaneous Immunoglobulin Market Size, by Strength, 2017-2032 (USD Million)
TABLE 79. North America Subcutaneous Immunoglobulin Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 80. North America Subcutaneous Immunoglobulin Market Size, by End User, 2017-2032 (USD Million)
TABLE 81. Latin America Subcutaneous Immunoglobulin Market Size, by Region, 2017-2032 (USD Million)
TABLE 82. Latin America Subcutaneous Immunoglobulin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 83. Latin America Subcutaneous Immunoglobulin Market Size, by Conventional Subcutaneous Immunoglobulin, 2017-2032 (USD Million)
TABLE 84. Latin America Subcutaneous Immunoglobulin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 85. Latin America Subcutaneous Immunoglobulin Market Size, by Primary Immunodeficiency, 2017-2032 (USD Million)
TABLE 86. Latin America Subcutaneous Immunoglobulin Market Size, by Secondary Immunodeficiency, 2017-2032 (USD Million)
TABLE 87. Latin America Subcutaneous Immunoglobulin Market Size, by Strength, 2017-2032 (USD Million)
TABLE 88. Latin America Subcutaneous Immunoglobulin Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 89. Latin America Subcutaneous Immunoglobulin Market Size, by End User, 2017-2032 (USD Million)
TABLE 90. Europe Subcutaneous Immunoglobulin Market Size, by Region, 2017-2032 (USD Million)
TABLE 91. Europe Subcutaneous Immunoglobulin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 92. Europe Subcutaneous Immunoglobulin Market Size, by Conventional Subcutaneous Immunoglobulin, 2017-2032 (USD Million)
TABLE 93. Europe Subcutaneous Immunoglobulin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 94. Europe Subcutaneous Immunoglobulin Market Size, by Primary Immunodeficiency, 2017-2032 (USD Million)
TABLE 95. Europe Subcutaneous Immunoglobulin Market Size, by Secondary Immunodeficiency, 2017-2032 (USD Million)
TABLE 96. Europe Subcutaneous Immunoglobulin Market Size, by Strength, 2017-2032 (USD Million)
TABLE 97. Europe Subcutaneous Immunoglobulin Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 98. Europe Subcutaneous Immunoglobulin Market Size, by End User, 2017-2032 (USD Million)
TABLE 99. Middle East Subcutaneous Immunoglobulin Market Size, by Region, 2017-2032 (USD Million)
TABLE 100. Middle East Subcutaneous Immunoglobulin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 101. Middle East Subcutaneous Immunoglobulin Market Size, by Conventional Subcutaneous Immunoglobulin, 2017-2032 (USD Million)
TABLE 102. Middle East Subcutaneous Immunoglobulin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 103. Middle East Subcutaneous Immunoglobulin Market Size, by Primary Immunodeficiency, 2017-2032 (USD Million)
TABLE 104. Middle East Subcutaneous Immunoglobulin Market Size, by Secondary Immunodeficiency, 2017-2032 (USD Million)
TABLE 105. Middle East Subcutaneous Immunoglobulin Market Size, by Strength, 2017-2032 (USD Million)
TABLE 106. Middle East Subcutaneous Immunoglobulin Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 107. Middle East Subcutaneous Immunoglobulin Market Size, by End User, 2017-2032 (USD Million)
TABLE 108. Africa Subcutaneous Immunoglobulin Market Size, by Region, 2017-2032 (USD Million)
TABLE 109. Africa Subcutaneous Immunoglobulin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 110. Africa Subcutaneous Immunoglobulin Market Size, by Conventional Subcutaneous Immunoglobulin, 2017-2032 (USD Million)
TABLE 111. Africa Subcutaneous Immunoglobulin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 112. Africa Subcutaneous Immunoglobulin Market Size, by Primary Immunodeficiency, 2017-2032 (USD Million)
TABLE 113. Africa Subcutaneous Immunoglobulin Market Size, by Secondary Immunodeficiency, 2017-2032 (USD Million)
TABLE 114. Africa Subcutaneous Immunoglobulin Market Size, by Strength, 2017-2032 (USD Million)
TABLE 115. Africa Subcutaneous Immunoglobulin Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 116. Africa Subcutaneous Immunoglobulin Market Size, by End User, 2017-2032 (USD Million)
TABLE 117. Global Subcutaneous Immunoglobulin Market Size, by Group, 2017-2032 (USD Million)
TABLE 118. ASEAN Subcutaneous Immunoglobulin Market Size, by Group, 2017-2032 (USD Million)
TABLE 119. ASEAN Subcutaneous Immunoglobulin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 120. ASEAN Subcutaneous Immunoglobulin Market Size, by Conventional Subcutaneous Immunoglobulin, 2017-2032 (USD Million)
TABLE 121. ASEAN Subcutaneous Immunoglobulin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 122. ASEAN Subcutaneous Immunoglobulin Market Size, by Primary Immunodeficiency, 2017-2032 (USD Million)
TABLE 123. ASEAN Subcutaneous Immunoglobulin Market Size, by Secondary Immunodeficiency, 2017-2032 (USD Million)
TABLE 124. ASEAN Subcutaneous Immunoglobulin Market Size, by Strength, 2017-2032 (USD Million)
TABLE 125. ASEAN Subcutaneous Immunoglobulin Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 126. ASEAN Subcutaneous Immunoglobulin Market Size, by End User, 2017-2032 (USD Million)
TABLE 127. GCC Subcutaneous Immunoglobulin Market Size, by Group, 2017-2032 (USD Million)
TABLE 128. GCC Subcutaneous Immunoglobulin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 129. GCC Subcutaneous Immunoglobulin Market Size, by Conventional Subcutaneous Immunoglobulin, 2017-2032 (USD Million)
TABLE 130. GCC Subcutaneous Immunoglobulin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 131. GCC Subcutaneous Immunoglobulin Market Size, by Primary Immunodeficiency, 2017-2032 (USD Million)
TABLE 132. GCC Subcutaneous Immunoglobulin Market Size, by Secondary Immunodeficiency, 2017-2032 (USD Million)
TABLE 133. GCC Subcutaneous Immunoglobulin Market Size, by Strength, 2017-2032 (USD Million)
TABLE 134. GCC Subcutaneous Immunoglobulin Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 135. GCC Subcutaneous Immunoglobulin Market Size, by End User, 2017-2032 (USD Million)
TABLE 136. European Union Subcutaneous Immunoglobulin Market Size, by Group, 2017-2032 (USD Million)
TABLE 137. European Union Subcutaneous Immunoglobulin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 138. European Union Subcutaneous Immunoglobulin Market Size, by Conventional Subcutaneous Immunoglobulin, 2017-2032 (USD Million)
TABLE 139. European Union Subcutaneous Immunoglobulin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 140. European Union Subcutaneous Immunoglobulin Market Size, by Primary Immunodeficiency, 2017-2032 (USD Million)
TABLE 141. European Union Subcutaneous Immunoglobulin Market Size, by Secondary Immunodeficiency, 2017-2032 (USD Million)
TABLE 142. European Union Subcutaneous Immunoglobulin Market Size, by Strength, 2017-2032 (USD Million)
TABLE 143. European Union Subcutaneous Immunoglobulin Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 144. European Union Subcutaneous Immunoglobulin Market Size, by End User, 2017-2032 (USD Million)
TABLE 145. BRICS Subcutaneous Immunoglobulin Market Size, by Group, 2017-2032 (USD Million)
TABLE 146. BRICS Subcutaneous Immunoglobulin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 147. BRICS Subcutaneous Immunoglobulin Market Size, by Conventional Subcutaneous Immunoglobulin, 2017-2032 (USD Million)
TABLE 148. BRICS Subcutaneous Immunoglobulin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 149. BRICS Subcutaneous Immunoglobulin Market Size, by Primary Immunodeficiency, 2017-2032 (USD Million)
TABLE 150. BRICS Subcutaneous Immunoglobulin Market Size, by Secondary Immunodeficiency, 2017-2032 (USD Million)
TABLE 151. BRICS Subcutaneous Immunoglobulin Market Size, by Strength, 2017-2032 (USD Million)
TABLE 152. BRICS Subcutaneous Immunoglobulin Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 153. BRICS Subcutaneous Immunoglobulin Market Size, by End User, 2017-2032 (USD Million)
TABLE 154. G7 Subcutaneous Immunoglobulin Market Size, by Group, 2017-2032 (USD Million)
TABLE 155. G7 Subcutaneous Immunoglobulin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 156. G7 Subcutaneous Immunoglobulin Market Size, by Conventional Subcutaneous Immunoglobulin, 2017-2032 (USD Million)
TABLE 157. G7 Subcutaneous Immunoglobulin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 158. G7 Subcutaneous Immunoglobulin Market Size, by Primary Immunodeficiency, 2017-2032 (USD Million)
TABLE 159. G7 Subcutaneous Immunoglobulin Market Size, by Secondary Immunodeficiency, 2017-2032 (USD Million)
TABLE 160. G7 Subcutaneous Immunoglobulin Market Size, by Strength, 2017-2032 (USD Million)
TABLE 161. G7 Subcutaneous Immunoglobulin Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 162. G7 Subcutaneous Immunoglobulin Market Size, by End User, 2017-2032 (USD Million)
TABLE 163. NATO Subcutaneous Immunoglobulin Market Size, by Group, 2017-2032 (USD Million)
TABLE 164. NATO Subcutaneous Immunoglobulin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 165. NATO Subcutaneous Immunoglobulin Market Size, by Conventional Subcutaneous Immunoglobulin, 2017-2032 (USD Million)
TABLE 166. NATO Subcutaneous Immunoglobulin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 167. NATO Subcutaneous Immunoglobulin Market Size, by Primary Immunodeficiency, 2017-2032 (USD Million)
TABLE 168. NATO Subcutaneous Immunoglobulin Market Size, by Secondary Immunodeficiency, 2017-2032 (USD Million)
TABLE 169. NATO Subcutaneous Immunoglobulin Market Size, by Strength, 2017-2032 (USD Million)
TABLE 170. NATO Subcutaneous Immunoglobulin Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 171. NATO Subcutaneous Immunoglobulin Market Size, by End User, 2017-2032 (USD Million)
TABLE 172. Global Subcutaneous Immunoglobulin Market Size, by Country, 2017-2032 (USD Million)
TABLE 173. United States Subcutaneous Immunoglobulin Market Size, 2017-2032 (USD Million)
TABLE 174. United States Subcutaneous Immunoglobulin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 175. United States Subcutaneous Immunoglobulin Market Size, by Conventional Subcutaneous Immunoglobulin, 2017-2032 (USD Million)
TABLE 176. United States Subcutaneous Immunoglobulin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 177. United States Subcutaneous Immunoglobulin Market Size, by Primary Immunodeficiency, 2017-2032 (USD Million)
TABLE 178. United States Subcutaneous Immunoglobulin Market Size, by Secondary Immunodeficiency, 2017-2032 (USD Million)
TABLE 179. United States Subcutaneous Immunoglobulin Market Size, by Strength, 2017-2032 (USD Million)
TABLE 180. United States Subcutaneous Immunoglobulin Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 181. United States Subcutaneous Immunoglobulin Market Size, by End User, 2017-2032 (USD Million)
TABLE 182. Canada Subcutaneous Immunoglobulin Market Size, 2017-2032 (USD Million)
TABLE 183. Canada Subcutaneous Immunoglobulin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 184. Canada Subcutaneous Immunoglobulin Market Size, by Conventional Subcutaneous Immunoglobulin, 2017-2032 (USD Million)
TABLE 185. Canada Subcutaneous Immunoglobulin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 186. Canada Subcutaneous Immunoglobulin Market Size, by Primary Immunodeficiency, 2017-2032 (USD Million)
TABLE 187. Canada Subcutaneous Immunoglobulin Market Size, by Secondary Immunodeficiency, 2017-2032 (USD Million)
TABLE 188. Canada Subcutaneous Immunoglobulin Market Size, by Strength, 2017-2032 (USD Million)
TABLE 189. Canada Subcutaneous Immunoglobulin Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 190. Canada Subcutaneous Immunoglobulin Market Size, by End User, 2017-2032 (USD Million)
TABLE 191. Mexico Subcutaneous Immunoglobulin Market Size, 2017-2032 (USD Million)
TABLE 192. Mexico Subcutaneous Immunoglobulin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 193. Mexico Subcutaneous Immunoglobulin Market Size, by Conventional Subcutaneous Immunoglobulin, 2017-2032 (USD Million)
TABLE 194. Mexico Subcutaneous Immunoglobulin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 195. Mexico Subcutaneous Immunoglobulin Market Size, by Primary Immunodeficiency, 2017-2032 (USD Million)
TABLE 196. Mexico Subcutaneous Immunoglobulin Market Size, by Secondary Immunodeficiency, 2017-2032 (USD Million)
TABLE 197. Mexico Subcutaneous Immunoglobulin Market Size, by Strength, 2017-2032 (USD Million)
TABLE 198. Mexico Subcutaneous Immunoglobulin Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 199. Mexico Subcutaneous Immunoglobulin Market Size, by End User, 2017-2032 (USD Million)
TABLE 200. Brazil Subcutaneous Immunoglobulin Market Size, 2017-2032 (USD Million)
TABLE 201. Brazil Subcutaneous Immunoglobulin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 202. Brazil Subcutaneous Immunoglobulin Market Size, by Conventional Subcutaneous Immunoglobulin, 2017-2032 (USD Million)
TABLE 203. Brazil Subcutaneous Immunoglobulin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 204. Brazil Subcutaneous Immunoglobulin Market Size, by Primary Immunodeficiency, 2017-2032 (USD Million)
TABLE 205. Brazil Subcutaneous Immunoglobulin Market Size, by Secondary Immunodeficiency, 2017-2032 (USD Million)
TABLE 206. Brazil Subcutaneous Immunoglobulin Market Size, by Strength, 2017-2032 (USD Million)
TABLE 207. Brazil Subcutaneous Immunoglobulin Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 208. Brazil Subcutaneous Immunoglobulin Market Size, by End User, 2017-2032 (USD Million)
TABLE 209. United Kingdom Subcutaneous Immunoglobulin Market Size, 2017-2032 (USD Million)
TABLE 210. United Kingdom Subcutaneous Immunoglobulin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 211. United Kingdom Subcutaneous Immunoglobulin Market Size, by Conventional Subcutaneous Immunoglobulin, 2017-2032 (USD Million)
TABLE 212. United Kingdom Subcutaneous Immunoglobulin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 213. United Kingdom Subcutaneous Immunoglobulin Market Size, by Primary Immunodeficiency, 2017-2032 (USD Million)
TABLE 214. United Kingdom Subcutaneous Immunoglobulin Market Size, by Secondary Immunodeficiency, 2017-2032 (USD Million)
TABLE 215. United Kingdom Subcutaneous Immunoglobulin Market Size, by Strength, 2017-2032 (USD Million)
TABLE 216. United Kingdom Subcutaneous Immunoglobulin Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 217. United Kingdom Subcutaneous Immunoglobulin Market Size, by End User, 2017-2032 (USD Million)
TABLE 218. Germany Subcutaneous Immunoglobulin Market Size, 2017-2032 (USD Million)
TABLE 219. Germany Subcutaneous Immunoglobulin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 220. Germany Subcutaneous Immunoglobulin Market Size, by Conventional Subcutaneous Immunoglobulin, 2017-2032 (USD Million)
TABLE 221. Germany Subcutaneous Immunoglobulin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 222. Germany Subcutaneous Immunoglobulin Market Size, by Primary Immunodeficiency, 2017-2032 (USD Million)
TABLE 223. Germany Subcutaneous Immunoglobulin Market Size, by Secondary Immunodeficiency, 2017-2032 (USD Million)
TABLE 224. Germany Subcutaneous Immunoglobulin Market Size, by Strength, 2017-2032 (USD Million)
TABLE 225. Germany Subcutaneous Immunoglobulin Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 226. Germany Subcutaneous Immunoglobulin Market Size, by End User, 2017-2032 (USD Million)
TABLE 227. France Subcutaneous Immunoglobulin Market Size, 2017-2032 (USD Million)
TABLE 228. France Subcutaneous Immunoglobulin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 229. France Subcutaneous Immunoglobulin Market Size, by Conventional Subcutaneous Immunoglobulin, 2017-2032 (USD Million)
TABLE 230. France Subcutaneous Immunoglobulin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 231. France Subcutaneous Immunoglobulin Market Size, by Primary Immunodeficiency, 2017-2032 (USD Million)
TABLE 232. France Subcutaneous Immunoglobulin Market Size, by Secondary Immunodeficiency, 2017-2032 (USD Million)
TABLE 233. France Subcutaneous Immunoglobulin Market Size, by Strength, 2017-2032 (USD Million)
TABLE 234. France Subcutaneous Immunoglobulin Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 235. France Subcutaneous Immunoglobulin Market Size, by End User, 2017-2032 (USD Million)
TABLE 236. Russia Subcutaneous Immunoglobulin Market Size, 2017-2032 (USD Million)
TABLE 237. Russia Subcutaneous Immunoglobulin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 238. Russia Subcutaneous Immunoglobulin Market Size, by Conventional Subcutaneous Immunoglobulin, 2017-2032 (USD Million)
TABLE 239. Russia Subcutaneous Immunoglobulin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 240. Russia Subcutaneous Immunoglobulin Market Size, by Primary Immunodeficiency, 2017-2032 (USD Million)
TABLE 241. Russia Subcutaneous Immunoglobulin Market Size, by Secondary Immunodeficiency, 2017-2032 (USD Million)
TABLE 242. Russia Subcutaneous Immunoglobulin Market Size, by Strength, 2017-2032 (USD Million)
TABLE 243. Russia Subcutaneous Immunoglobulin Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 244. Russia Subcutaneous Immunoglobulin Market Size, by End User, 2017-2032 (USD Million)
TABLE 245. Italy Subcutaneous Immunoglobulin Market Size, 2017-2032 (USD Million)
TABLE 246. Italy Subcutaneous Immunoglobulin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 247. Italy Subcutaneous Immunoglobulin Market Size, by Conventional Subcutaneous Immunoglobulin, 2017-2032 (USD Million)
TABLE 248. Italy Subcutaneous Immunoglobulin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 249. Italy Subcutaneous Immunoglobulin Market Size, by Primary Immunodeficiency, 2017-2032 (USD Million)
TABLE 250. Italy Subcutaneous Immunoglobulin Market Size, by Secondary Immunodeficiency, 2017-2032 (USD Million)
TABLE 251. Italy Subcutaneous Immunoglobulin Market Size, by Strength, 2017-2032 (USD Million)
TABLE 252. Italy Subcutaneous Immunoglobulin Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 253. Italy Subcutaneous Immunoglobulin Market Size, by End User, 2017-2032 (USD Million)
TABLE 254. Spain Subcutaneous Immunoglobulin Market Size, 2017-2032 (USD Million)
TABLE 255. Spain Subcutaneous Immunoglobulin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 256. Spain Subcutaneous Immunoglobulin Market Size, by Conventional Subcutaneous Immunoglobulin, 2017-2032 (USD Million)
TABLE 257. Spain Subcutaneous Immunoglobulin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 258. Spain Subcutaneous Immunoglobulin Market Size, by Primary Immunodeficiency, 2017-2032 (USD Million)
TABLE 259. Spain Subcutaneous Immunoglobulin Market Size, by Secondary Immunodeficiency, 2017-2032 (USD Million)
TABLE 260. Spain Subcutaneous Immunoglobulin Market Size, by Strength, 2017-2032 (USD Million)
TABLE 261. Spain Subcutaneous Immunoglobulin Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 262. Spain Subcutaneous Immunoglobulin Market Size, by End User, 2017-2032 (USD Million)
TABLE 263. China Subcutaneous Immunoglobulin Market Size, 2017-2032 (USD Million)
TABLE 264. China Subcutaneous Immunoglobulin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 265. China Subcutaneous Immunoglobulin Market Size, by Conventional Subcutaneous Immunoglobulin, 2017-2032 (USD Million)
TABLE 266. China Subcutaneous Immunoglobulin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 267. China Subcutaneous Immunoglobulin Market Size, by Primary Immunodeficiency, 2017-2032 (USD Million)
TABLE 268. China Subcutaneous Immunoglobulin Market Size, by Secondary Immunodeficiency, 2017-2032 (USD Million)
TABLE 269. China Subcutaneous Immunoglobulin Market Size, by Strength, 2017-2032 (USD Million)
TABLE 270. China Subcutaneous Immunoglobulin Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 271. China Subcutaneous Immunoglobulin Market Size, by End User, 2017-2032 (USD Million)
TABLE 272. India Subcutaneous Immunoglobulin Market Size, 2017-2032 (USD Million)
TABLE 273. India Subcutaneous Immunoglobulin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 274. India Subcutaneous Immunoglobulin Market Size, by Conventional Subcutaneous Immunoglobulin, 2017-2032 (USD Million)
TABLE 275. India Subcutaneous Immunoglobulin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 276. India Subcutaneous Immunoglobulin Market Size, by Primary Immunodeficiency, 2017-2032 (USD Million)
TABLE 277. India Subcutaneous Immunoglobulin Market Size, by Secondary Immunodeficiency, 2017-2032 (USD Million)
TABLE 278. India Subcutaneous Immunoglobulin Market Size, by Strength, 2017-2032 (USD Million)
TABLE 279. India Subcutaneous Immunoglobulin Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 280. India Subcutaneous Immunoglobulin Market Size, by End User, 2017-2032 (USD Million)
TABLE 281. Japan Subcutaneous Immunoglobulin Market Size, 2017-2032 (USD Million)
TABLE 282. Japan Subcutaneous Immunoglobulin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 283. Japan Subcutaneous Immunoglobulin Market Size, by Conventional Subcutaneous Immunoglobulin, 2017-2032 (USD Million)
TABLE 284. Japan Subcutaneous Immunoglobulin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 285. Japan Subcutaneous Immunoglobulin Market Size, by Primary Immunodeficiency, 2017-2032 (USD Million)
TABLE 286. Japan Subcutaneous Immunoglobulin Market Size, by Secondary Immunodeficiency, 2017-2032 (USD Million)
TABLE 287. Japan Subcutaneous Immunoglobulin Market Size, by Strength, 2017-2032 (USD Million)
TABLE 288. Japan Subcutaneous Immunoglobulin Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 289. Japan Subcutaneous Immunoglobulin Market Size, by End User, 2017-2032 (USD Million)
TABLE 290. Australia Subcutaneous Immunoglobulin Market Size, 2017-2032 (USD Million)
TABLE 291. Australia Subcutaneous Immunoglobulin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 292. Australia Subcutaneous Immunoglobulin Market Size, by Conventional Subcutaneous Immunoglobulin, 2017-2032 (USD Million)
TABLE 293. Australia Subcutaneous Immunoglobulin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 294. Australia Subcutaneous Immunoglobulin Market Size, by Primary Immunodeficiency, 2017-2032 (USD Million)
TABLE 295. Australia Subcutaneous Immunoglobulin Market Size, by Secondary Immunodeficiency, 2017-2032 (USD Million)
TABLE 296. Australia Subcutaneous Immunoglobulin Market Size, by Strength, 2017-2032 (USD Million)
TABLE 297. Australia Subcutaneous Immunoglobulin Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 298. Australia Subcutaneous Immunoglobulin Market Size, by End User, 2017-2032 (USD Million)
TABLE 299. South Korea Subcutaneous Immunoglobulin Market Size, 2017-2032 (USD Million)
TABLE 300. South Korea Subcutaneous Immunoglobulin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 301. South Korea Subcutaneous Immunoglobulin Market Size, by Conventional Subcutaneous Immunoglobulin, 2017-2032 (USD Million)
TABLE 302. South Korea Subcutaneous Immunoglobulin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 303. South Korea Subcutaneous Immunoglobulin Market Size, by Primary Immunodeficiency, 2017-2032 (USD Million)
TABLE 304. South Korea Subcutaneous Immunoglobulin Market Size, by Secondary Immunodeficiency, 2017-2032 (USD Million)
TABLE 305. South Korea Subcutaneous Immunoglobulin Market Size, by Strength, 2017-2032 (USD Million)
TABLE 306. South Korea Subcutaneous Immunoglobulin Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 307. South Korea Subcutaneous Immunoglobulin Market Size, by End User, 2017-2032 (USD Million)
TABLE 308. Global Subcutaneous Immunoglobulin Market Share, by Key Player, 2025
TABLE 309. Global Subcutaneous Immunoglobulin Market, Key Experts

Companies Mentioned

  • ADMA Biologics, Inc.
  • argenx SE
  • Baxter International Inc.
  • Biological E. Limited
  • CSL Limited
  • Emergent BioSolutions Inc.
  • Grifols, S.A.
  • Intas Pharmaceuticals Limited
  • Japan Blood Products Organization
  • Kamada Ltd.
  • LFB S.A.
  • Octapharma AG
  • Pfizer Inc.
  • Sanquin Health Solutions B.V.
  • Shanghai RAAS Blood Products Co., Ltd.
  • Takeda Pharmaceutical Company Limited

Related Topics

Related Reports

Subcutaneous Immunoglobulin - Global Strategic Business Report - Product Image

Subcutaneous Immunoglobulin - Global Strategic Business Report

  • Report
  • 226 Pages
  • Global
From
Immunoglobulin Product Market - Global Forecast 2026-2032 - Product Image

Immunoglobulin Product Market - Global Forecast 2026-2032

  • Report
  • 181 Pages
  • Global
From
Subcutaneous Immunoglobulin (SCIG) Market Report 2026 - Product Image

Subcutaneous Immunoglobulin (SCIG) Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Subcutaneous Immunoglobulin Market Outlook 2026-2034: Market Share, and Growth Analysis by Application, Administration Technique, End User, Distribution Channel - Product Image

Subcutaneous Immunoglobulin Market Outlook 2026-2034: Market Share, and Growth Analysis by Application, Administration Technique, End User, Distribution Channel

  • Report
  • 160 Pages
  • Global
From
Immunoglobulins Market Report 2026 - Product Image

Immunoglobulins Market Report 2026

  • Report
  • 250 Pages
  • Global
From

About the Subcutaneous Immunoglobulin Market

The Subcutaneous Immunoglobulin (SCIg) market is a segment of the Immune Disorders Drugs market. SCIg is a form of immunoglobulin therapy used to treat a variety of immune-mediated diseases, such as primary immunodeficiencies, autoimmune diseases, and chronic inflammatory diseases. SCIg is administered through subcutaneous injections, which are less painful and more convenient than intravenous infusions. SCIg is also more cost-effective than intravenous immunoglobulin (IVIg). SCIg is a rapidly growing market, driven by the increasing prevalence of immune-mediated diseases and the growing demand for more convenient and cost-effective treatments. The market is expected to continue to grow in the coming years, as more patients are diagnosed with immune-mediated diseases and as new treatments become available. Some of the major players in the SCIg market include CSL Behring, Grifols, Kedrion, Octapharma, and Shire. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.